Treatment
Inhaled Treprostinil clinical trials
We’re tracking 11 recruiting studies that include Inhaled Treprostinil, each written for real people, not researchers, below.
Recruiting studies
- NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Birmingham, AlabamaAges 18 years+ - NCT07037836RecruitingPhase 2
Inhaled treprostinil for COPD with low oxygen
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
Durham, North CarolinaAges 40 years+ - NCT07759804RecruitingPhase 4
Switching from selexipag to inhaled treprostinil for pulmonary arterial hypertension
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
Columbus, GeorgiaAges 18–80 - NCT07481981RecruitingPhase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Los Angeles, CaliforniaAges 18–75 - NCT07643155RecruitingPhase 1
Safety study of inhaled treprostinil in people with liver disease
This early-stage study tests how the body processes a new inhaled breathing medication (treprostinil) and whether it's safe in people with normal liver function and those with chronic liver disease. The goal is to understand if the medication works differently depending on liver health.
Lake Forest, CaliforniaAges 18–70 - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT07179380RecruitingPhase 3
Inhaled treprostinil for pulmonary hypertension related to interstitial lung disease
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Phoenix, ArizonaAges 18 years+ - NCT07837830RecruitingEarly Phase 1
Early treatment for exercise-related lung pressure
This trial tests an inhaled medicine that may help people with lung scarring or connective tissue disease who have high blood pressure in the lungs only during exercise. It aims to improve their ability to be active and reduce symptoms.
Paramus, New JerseyAges 18 years+ - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Santa Barbara, CaliforniaAges 18–85 - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Phoenix, ArizonaAges 18–80
What Inhaled Treprostinil is being studied for
Conditions with recruiting Inhaled Treprostinil studies.
Common questions
- Are there clinical trials studying Inhaled Treprostinil?
- Yes. Clin2 currently lists 11 recruiting studies that include Inhaled Treprostinil, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Inhaled Treprostinil trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Inhaled Treprostinil an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Inhaled Treprostinil or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.